This post is taken from IZULAT blog repost here
Rheumatoid
arthritis drug tocilizumab has recently found to be effective in treating
severe cases of COVID-19 however, other experts urged a caution until the full
results is released for some are already confident of it and stop making trials
of it.
“Preliminary trial data has suggested that
tocilizumab may be effective in improving outcomes for patients severely
affected by the SARS-CoV-2 virus;
however, full results are still awaited. On 20-11-2020 the word was
spread that a worldwide survey had shown that tocilizumab may, in half of the
severe covid-19 cases, lead to less death, shorter stay in hospitals (IC's) and
less dependency on support of vital functions.”(Wikipedia)
“Tocilizumab (INN, trade
name Actemra), also known as atlizumab, is an immunosuppressive
drug, mainly for the treatment of rheumatoid
arthritis (RA) and systemic
juvenile idiopathic arthritis, a severe form of
arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that
plays an important role in immune response and is implicated in the
pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.”(Wikipedia)
 |
| image from Science News website |
No comments:
Post a Comment